Jamie Cavenagh - Concepedia

Author

Jamie Cavenagh

Also Known As

J Cavenagh, J D Cavenagh, J. CAVENAGH, J. Cavenagh, J. D. CAVENAGH, J. D. Cavenagh, J.D. Cavenagh, Jamie Cavenagh, Jamie D Cavenagh, Jamie D. Cavenagh

240

Publications

16.9K

Citations

H-Index

Concepts

All Affiliations

St Bartholomew's Hospital University College London Barts Health NHS Trust Royal London Hospital University of Birmingham

About

Jamie Cavenagh is an author at St Bartholomew's Hospital specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	36	4.4K
2	Health Sciences	17	17	2.9K
3	Cell Biology	5	5	916
4	Blood Transplantation	2	2	29
5	Public Health	1	1	367

Jamie Cavenagh

Publications

14.6K

Citations

H-Index

Page 1

	Year	Citations
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, New England Journal of Medicine	2005	2.5K
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon, The Lancet Oncology Hematological MalignancyDouble-blind Phase 3MedicineDexamethasone Versus PlaceboHematology	2014	781
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri, New England Journal of Medicine	2014	780
Guidelines for the diagnosis and management of adult aplastic anaemia Sally Killick, Nick Bown, Jamie Cavenagh, British Journal of Haematology	2015	729
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia Nicolas Goardon, Emanuele Marchi, Ann Atzberger, Cancer Cell Hematological MalignancyDevelopmental BiologyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2011	634
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Paul G. Richardson, Pieter Sonneveld, Michael Schuster, Blood	2007	509
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura Marie Scully, Vickie McDonald, Jamie Cavenagh, Blood	2011	413
Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features Marie Scully, Helen Yarranton, Ri Liesner, British Journal of Haematology DiagnosisPathologyClinical FeaturesSouth EastThrombosis	2008	367
Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells David Taussig, Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Blood	2008	361
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction David Taussig, Jacques Vargaftig, Farideh Miraki‐Moud, Blood	2010	356

Page 1